Ocular Therapeutix, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
OCUL Nasdaq 2836 www.ocutx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ocular Therapeutix, Inc.

Ocular Therapeutix (OCUL) Stock Still Looks Pricey As 145% Gain Draws Scrutiny - Oct 2nd, 2026 8:09 am
3 of Wall Street’s Favorite Stocks That Fall Short - Oct 2nd, 2026 5:10 am
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD - Oct 1st, 2026 3:35 pm
3 Reasons to Avoid OCUL and 1 Stock to Buy Instead - Oct 1st, 2026 10:53 am
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences - Oct 1st, 2026 5:00 am
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs - Sep 28th, 2026 11:15 am
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know - Sep 23rd, 2026 3:38 pm
Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst? - Sep 23rd, 2026 4:32 am
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success - Sep 22nd, 2026 9:02 pm
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 18th, 2026 5:00 am
Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday - Sep 15th, 2026 7:12 am
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD - Sep 15th, 2026 5:00 am
Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs - Sep 3rd, 2026 5:06 am
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences - Sep 1st, 2026 5:00 am
1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges - Sep 1st, 2026 4:10 am
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update - Aug 22nd, 2026 8:08 am
Ocular Therapeutix (OCUL) Could Be 59% Undervalued Following Earnings Beat And AXPAXLI Progress - Aug 22nd, 2026 12:10 am
Ocular Therapeutix (OCUL) Stock Fair Value Edges Higher After Analyst Target Increases - Aug 21st, 2026 7:12 pm
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Aug 21st, 2026 1:47 pm
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why - Aug 17th, 2026 5:51 pm